

**\*\*\*Pharmacy Notice\*\*\*****Magellan Medicaid Administration (MMA)****Louisiana Medicaid Single Managed Care Organization****(MCO) Pharmacy Benefits Manager (PBM)****\*\*\*GLP-1s Therapeutic Duplication\*\*\*****September 26, 2024**

The Louisiana Medicaid Preferred Drug List (PDL) has several point of sale (POS) safety edits on Glucagon-like peptide-1 (GLP-1) agonists, including a therapeutic duplication edit. GLP-1 receptor agonists are monitored at the pharmacy POS for duplication of therapy with other GLP-1 receptor agonists or DPP-4 inhibitors. Currently, if a pharmacy claim submitted hits one of these edits, it will reject and allow for the pharmacist to override at POS if the duplicate therapy is verified as appropriate with the prescriber.

Link to access the PDL's GLP-1 POS document:

[POS.Diabetes.Hypoglycemics.Incretin.Mimetics.Enhancers.02062024.AprDUR.pdf \(la.gov\)](https://ldh.la.gov/assets/docs/BayouHealth/Pharmacy/DrugPA_FormCoversheet.pdf)

Effective October 1, 2024, GLP-1s therapeutic duplication can no longer be overridden at POS. If a therapeutic duplication override is needed, the prescriber must complete a prior authorization justifying the need for prescribing GLP-1 agonists outside of these limits.

The Louisiana Uniform Prescription Drug Prior Authorization Form

[https://ldh.la.gov/assets/docs/BayouHealth/Pharmacy/DrugPA\\_FormCoversheet.pdf](https://ldh.la.gov/assets/docs/BayouHealth/Pharmacy/DrugPA_FormCoversheet.pdf) should be utilized by providers to request prior authorization to override the therapeutic duplication edit for the following agents:

- GLP-1 with DPP-4
- DPP-4 with DPP-4
- GLP-1 with GLP-1
- DPP-4 with GLP-1

This is necessary to ensure appropriate utilization for the GLP-1 agonists.

If you have any questions or concerns, please call Magellan at 1-800-424-1664.

Thank you,

Magellan Medicaid Administration

BIN#	025986
Processor Control #	1214172240
Group	LAMCOPBM